“Right now, people with bronchiectasis have no approved treatments to prevent pulmonary exacerbations that define this disease and can lead to destruction of lung tissue, putting hundreds of ...

Macrolide maintenance therapy in patients with bronchiectasis significantly reduces the risk for major adverse cardiovascular events.

In bronchiectasis, the walls of the airways become thickened and damaged as a result of a cycle of inflammation and infections. It is characterised by repeated exacerbations or attacks ...

Bronchiectasis affects approximately 450,000 ... to prescribe its drug to patients who had experienced two or more “exacerbations.” Wall Street analysts have speculated that, if approved ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024More prescriptions filled through February ...

Q4 2024 Earnings Call Transcript February 27, 2025 Verona Pharma plc misses on earnings expectations. Reported EPS is $-0.4 ...

Cefixime is commonly used to treat a variety of bacterial infections, including acute bronchitis, chronic bronchitis exacerbations, bronchiectasis with infection, secondary infections in chronic ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...

In 2025, the expected U.S. launch of brensocatib in bronchiectasis in the third ... to prescribe brensocatib to patients with two or more exacerbations upon approval. On pricing, we continue ...

Permanent changes such as bronchiectasis may persist ... with moderate doses of inhaled corticosteroids and has had two exacerbations over the past 3 years requiring oral steroids Case 3: A ...

In the past 60 days, estimates for Castle Biosciences’ 2025 loss per share have narrowed from $1.84 to $1.51. In the past year, shares of CSTL have risen 16.7%. CSTL’s earnings beat estimates ...